Ad
related to: sio gene therapies
Search results
Results From The WOW.Com Content Network
Sio Gene Therapies. Sio Gene Therapies, Inc. (formerly known as Axovant Gene Therapies) was a clinical-stage pharmaceutical company that developed gene therapies to treat neurological disorders. The company was headquartered in New York City and was incorporated in Basel, Switzerland. The company was founded by former hedge fund analyst and ...
Sio Gene Therapies Inc (NASDAQ: SIOX) has dosed the first patient in Phase 1/2 trial evaluating AXO-AAV-GM2 investigational gene therapy to treat GM2 gangliosidosis, also known as Tay-Sachs or ...
Axovant, owned by Roivant's Sio Gene Therapies, which failed testing in the end, has been accused of being a pump-and-dump scheme. In December 2023, Roche completed the acquisition of Telavant from Roivant for a purchase price of $7.1 billion upfront and a near-term milestone payment of $150 million.
Nelotanserin (former developmental code name APD-125) is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT 2A and was under development for the treatment of insomnia. [1]
Takeaways from AP's report on access to gene therapies for rare diseases. LAURA UNGAR. June 21, 2024 at 12:42 AM. The promise of gene therapy looms large for families dealing with rare, genetic ...
For premium support please call: 800-290-4726 more ways to reach us
Gene therapies. Alipogene tiparvovec (Glybera): AAV-based treatment for lipoprotein lipase deficiency (no longer commercially available) Axicabtagene ciloleucel (Yescarta): treatment for large B-cell lymphoma [1] Beremagene geperpavec (Vyjuvek): treatment of wounds.
For premium support please call: 800-290-4726 more ways to reach us
Ad
related to: sio gene therapies